Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupFRA:6MD 93 Days Payable is 79.22 as of Dec. 2025, which is 3% above its 10-year median of 77.22. GuruFocus rates FRA:6MD with a GF Score™ of 93/100 and a GF Value™ of €180.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Medacta Group ranks better than 53.84% on this metric.
The historical rank and industry rank for Medacta Group's Days Payable or its related term are showing as below:
FRA:6MD'
s Days Payable Range Over the Past 10 Years
Min: 69.09 Med: 77.22 Max: 106.24
Current: 73.58
During the past 11 years, Medacta Group's highest Days Payable was 106.24. The lowest was 69.09. And the median was 77.22.
FRA:6MD's Days Payable is ranked better than 53.84% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs FRA:6MD: 73.58
Medacta Group's Days Payable
increased
from Dec. 2024 (72.37) to Dec. 2025 (79.22).
It may suggest that Medacta Groupdelayed paying its suppliers.
Medacta Group Days Payable Related Terms
Medacta Group Days Payable Historical Data
* Premium members only.
The historical data trend for Medacta Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Medacta Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medacta Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (FRA:6MD) has a Days Payable of 79.22 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medacta Group and its competitors. This is near median its historical median of 77.22. Over the past decade, Medacta Group's Days Payable has ranged from 69.09 to 106.24. According to the industry distribution chart, Medacta Group ranks #367 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 46.2%.
Is Medacta Group's Days Payable too high?
Medacta Group's current Days Payable of 79.22 is near median its 10-year median of 77.22. Over the past 10 years, this metric has ranged from a low of 69.09 to a high of 106.24. The Medical Devices & Instruments industry median Days Payable is 67.87. Medacta Group's value of 79.22 is 16.7% above this industry median. Based on the distribution chart, Medacta Group ranks #367 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #367 out of 795 companies for Days Payable. This puts Medacta Group in the upper half of its industry. The industry median Days Payable is 67.87. Medacta Group's value of 79.22 is 16.7% above this benchmark. Historically, Medacta Group's own Days Payable has ranged from 69.09 to 106.24 over the past decade. While the company's 10-year median is 77.22 vs. the industry median of 67.87, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current Days Payable of 79.22 is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Days Payable is 79.22, which is near median its own 10-year median of 77.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €180.03, compared to a current price of €146.00 — trading 18.9% below its estimated fair value. The current Days Payable is 79.22, which is near median its 10-year median of 77.22 and 16.7% above the Medical Devices & Instruments industry median of 67.87. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current Days Payable is 79.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (FRA:6MD) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of €146.00 is trading 18.9% below its estimated GF Value™ of €180.03.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for FRA:6MD:
Days Payable: 79.22 (near median its 10-year median of 77.22)
GF Value™: €180.03 vs. price of €146.00 (18.9% below fair value)
Industry Position: 16.7% above the Medical Devices & Instruments median (#367 of 795)
No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score
Get the complete analysis for FRA:6MD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6MD has been successfully added to your 
